Improved safety and efficacy of AmBisome (liposomal amphotericin B, L-AmB) vs. amphotericin B (CAB) in the empirical treatment of febrile neutropenic patients undergoing BMT.

被引：0
|
作者：
Cagnoni, PJ [1 ]
Grethlein, S [1 ]
Korones, DN [1 ]
Goldman, M [1 ]
Kaizer, H [1 ]
机构：
[1] Empir Antifungal Study Grp, Denver, CO USA
来源：
BONE MARROW TRANSPLANTATION | 1999年 / 23卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
361
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [1] Improved safety and efficacy of amBisome (liposomal amphotericin B) compared with amphotericin B in the empirical treatment of febrile neutropenic patients undergoing bone marrow transplantation.
    Cagnoni, PJ
    Grethlein, S
    Korones, DN
    Goldman, M
    Kaizer, H
    BLOOD, 1997, 90 (10) : 1866 - 1866
  • [2] Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children
    Sunakawa, Keisuke
    Tsukimoto, Ichiro
    Tsunematsu, Yukiko
    Honda, Masatada
    Iwai, Naoichi
    Maniwa, Takashi
    Haigo, Hisamatsu
    Suzuki, Kota
    Mori, Takeshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2012, 18 (04) : 456 - 465
  • [3] Cost-Efficacy analysis of Liposomal Amphotericin B (L-AmB) versus Amphotericin B Lipid Complex (ABLC) in the empirical treatment of febrile neutropenia
    Eandi, Mario
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (04) : 333 - 347
  • [4] Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
    Cagnoni, PJ
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 : 81 - 86
  • [5] Amphotericin B colloidal dispersion (ABCD) vs amphotericin B (AmB) in the empiric treatment of febrile neutropenic patients.
    White, MH
    Bowden, RA
    Sandler, E
    Graham, ML
    Noskin, G
    Wingard, JR
    Goldman, M
    McCabe, A
    Lin, JS
    Gurwith, M
    Miller, CB
    BLOOD, 1996, 88 (10) : 1196 - 1196
  • [6] Empirical antifungal therapy (Rx) with caspofungin (CAS) vs liposomal amphotericin B (L-AmB) for persistently febrile neutropenic patients (pts) with acute myeloid leukemia (AML).
    Maertens, JA
    Teppler, H
    Lupinacci, R
    Bourque, M
    DiNubile, M
    Sable, C
    BLOOD, 2004, 104 (11) : 376A - 376A
  • [7] Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
    Cagnoni, PJ
    Walsh, TJ
    Prendergast, MM
    Bodensteiner, D
    Hiemenz, S
    Greenberg, RN
    Arndt, CAS
    Schuster, M
    Seibel, N
    Yeldandi, V
    Tong, KB
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) : 2476 - 2483
  • [8] LIPOSOMAL AMPHOTERICIN-B (AMBISOME) IN THE TREATMENT OF FUNGAL-INFECTIONS IN NEUTROPENIC PATIENTS
    CHOPRA, R
    BLAIR, S
    STRANG, J
    CERVI, P
    PATTERSON, KG
    GOLDSTONE, AH
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 : 93 - 104
  • [9] Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients
    Walsh, TJ
    Yeldandi, V
    McEvoy, M
    Gonzalez, C
    Chanock, S
    Freifeld, A
    Seibel, NI
    Whitcomb, PO
    Jarosinski, P
    Boswell, G
    Bekersky, I
    Alak, A
    Buell, D
    Barret, J
    Wilson, W
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2391 - 2398
  • [10] LIPOSOMAL AMPHOTERICIN B (L-AMB) TWICE WEEKLY AS ANTIFUNGAL PROPHYLAXIS IN PEDIACTRIC CANCER PATIENTS
    Lehrnbecher, Thomas
    Schedler, Nadine
    Tramsen, Lars
    Becker, Martina
    Klingebiel, Thomas
    Bochennek, Konrad
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 948 - 949
12345